Condition
Exudative Age Related Macular Degeneration
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
40%
2 of 5 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (2)
P 4 (1)
Trial Status
Completed5
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT04075136Phase 4WithdrawnPrimary
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
NCT04723160Completed
Computer Aided Diagnosis of Multiple Eye Fundus Diseases From Color Fundus Photograph
NCT03071055Phase 2CompletedPrimary
Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF
NCT02732899Phase 2CompletedPrimary
Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD
NCT01819415Not ApplicableCompletedPrimary
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
NCT00927303CompletedPrimary
The Spectralis-Cirrus Study
Showing all 6 trials